SK bioscience Co.,Ltd.
KSC: 302440.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jae-Yong Ahn
- Employees
- 984
- Headquarters
- Seongnam-si, South Korea
- IPO year
- 2021
- Market cap
- ₩3.3T
- Website
- https://www.skbioscience.co.kr
Loading 302440…
Loading profile data…Frequently asked questions about 302440
What does SK bioscience Co.,Ltd. (302440.KS) do?
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shi...
Where does 302440.KS trade?
SK bioscience Co.,Ltd. (302440.KS) trades on the Korea Exchange.
What sector is 302440.KS in?
SK bioscience Co.,Ltd. (302440.KS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SK bioscience Co.,Ltd.?
Jae-Yong Ahn is the chief executive officer of SK bioscience Co.,Ltd. (302440.KS).
Where is SK bioscience Co.,Ltd. headquartered?
SK bioscience Co.,Ltd. is headquartered in South Korea.
Does 302440.KS pay a dividend?
SK bioscience Co.,Ltd. (302440.KS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 302440.KS go public?
SK bioscience Co.,Ltd. (302440.KS) completed its initial public offering in 2021.